[go: up one dir, main page]

RU2008132204A - Соединения для лечения метаболических заболеваний - Google Patents

Соединения для лечения метаболических заболеваний Download PDF

Info

Publication number
RU2008132204A
RU2008132204A RU2008132204/04A RU2008132204A RU2008132204A RU 2008132204 A RU2008132204 A RU 2008132204A RU 2008132204/04 A RU2008132204/04 A RU 2008132204/04A RU 2008132204 A RU2008132204 A RU 2008132204A RU 2008132204 A RU2008132204 A RU 2008132204A
Authority
RU
Russia
Prior art keywords
compounds
treatment
metabolic diseases
perfluoromethoxy
perfluoromethyl
Prior art date
Application number
RU2008132204/04A
Other languages
English (en)
Other versions
RU2502723C2 (ru
Inventor
Шалини ШАРМА (US)
Шалини ШАРМА
БОРСТЕЛЬ Райд В. ФОН (US)
БОРСТЕЛЬ Райд В. ФОН
Кирвин Л. ХОДЖ (US)
Кирвин Л. ХОДЖ
Майкл К. БАМАТ (US)
Майкл К. БАМАТ
Стефен Д. УОЛП (US)
Стефен Д. УОЛП
Original Assignee
Веллстат Терапьютикс Корпорейшн (Us)
Веллстат Терапьютикс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Веллстат Терапьютикс Корпорейшн (Us), Веллстат Терапьютикс Корпорейшн filed Critical Веллстат Терапьютикс Корпорейшн (Us)
Publication of RU2008132204A publication Critical patent/RU2008132204A/ru
Application granted granted Critical
Publication of RU2502723C2 publication Critical patent/RU2502723C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B41/00—Formation or introduction of functional groups containing oxygen
    • C07B41/12—Formation or introduction of functional groups containing oxygen of carboxylic acid ester groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/10—Aromatic or araliphatic carboxylic acids, or thio analogues thereof; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/44—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/31—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/47—Preparation of carboxylic acid esters by telomerisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1. Соединение формулы ! ! где m равно 1; n равно 1 или 2; t равно 0 или 1; и A представляет собой фенил, замещенный 2 группами, выбранными из галогена, алкила, содержащего 1 или 2 атома углерода, перфторметила и перфторметокси. ! 2. Соединение формулы ! ! где m равно 1; n равно 1 или 2; t равно 0 или 1; и A представляет собой фенил, замещенный 2 группами, выбранными из: галогена, алкила, содержащего 1 или 2 атома углерода, перфторметила и перфторметокси.

Claims (2)

1. Соединение формулы
Figure 00000001
где m равно 1; n равно 1 или 2; t равно 0 или 1; и A представляет собой фенил, замещенный 2 группами, выбранными из галогена, алкила, содержащего 1 или 2 атома углерода, перфторметила и перфторметокси.
2. Соединение формулы
Figure 00000002
где m равно 1; n равно 1 или 2; t равно 0 или 1; и A представляет собой фенил, замещенный 2 группами, выбранными из: галогена, алкила, содержащего 1 или 2 атома углерода, перфторметила и перфторметокси.
RU2008132204/04A 2001-06-12 2008-08-04 Соединения для лечения метаболических заболеваний RU2502723C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29728201P 2001-06-12 2001-06-12
US60/297,282 2001-06-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2004100306/04A Division RU2341513C2 (ru) 2001-06-12 2002-06-12 Соединения для лечения метаболических заболеваний

Publications (2)

Publication Number Publication Date
RU2008132204A true RU2008132204A (ru) 2010-02-10
RU2502723C2 RU2502723C2 (ru) 2013-12-27

Family

ID=23145636

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2004100306/04A RU2341513C2 (ru) 2001-06-12 2002-06-12 Соединения для лечения метаболических заболеваний
RU2008132204/04A RU2502723C2 (ru) 2001-06-12 2008-08-04 Соединения для лечения метаболических заболеваний

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2004100306/04A RU2341513C2 (ru) 2001-06-12 2002-06-12 Соединения для лечения метаболических заболеваний

Country Status (19)

Country Link
US (23) US7101910B2 (ru)
EP (1) EP1461323B1 (ru)
JP (4) JP4711621B2 (ru)
KR (4) KR101009472B1 (ru)
CN (4) CN102151262A (ru)
AU (3) AU2002345625B2 (ru)
BR (1) BRPI0210383B1 (ru)
CA (1) CA2450221C (ru)
CZ (1) CZ20033394A3 (ru)
ES (1) ES2441874T3 (ru)
HU (1) HU230352B1 (ru)
IL (5) IL159320A0 (ru)
MX (1) MXPA03011558A (ru)
NO (2) NO333355B1 (ru)
NZ (1) NZ530051A (ru)
RU (2) RU2341513C2 (ru)
UA (2) UA104987C2 (ru)
WO (1) WO2002100341A2 (ru)
ZA (1) ZA200309627B (ru)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670358B2 (en) 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides
EP1461323B1 (en) * 2001-06-12 2013-10-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2006500315A (ja) * 2002-01-11 2006-01-05 アボット・ラボラトリーズ 糖尿病状態に用いるヒスタミン−３受容体リガンド
JP2006507303A (ja) * 2002-11-01 2006-03-02 ウェルスタット セラピューティクス コーポレイション 代謝障害の処置のための化合物
JP4697962B2 (ja) * 2003-02-13 2011-06-08 ウェルスタット セラピューティクス コーポレイション 代謝性障害の処置のための化合物
CA2521621C (en) * 2003-04-15 2011-11-01 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
ATE450496T1 (de) * 2003-04-22 2009-12-15 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
AU2004237602B2 (en) * 2003-04-30 2009-05-28 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EA200501710A1 (ru) 2003-04-30 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Замещённые карбоновые кислоты
US7348338B2 (en) * 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
RU2356889C2 (ru) * 2003-07-17 2009-05-27 Плекссикон, Инк. Соединения, являющиеся активными по отношению к рецепторам, активируемым пролифератором пероксисом
JP4703563B2 (ja) * 2003-08-20 2011-06-15 ウェルスタット セラピューティクス コーポレイション 代謝障害を治療するための化合物
CN1972715A (zh) * 2004-03-29 2007-05-30 三共株式会社 含有胰岛素抵抗改善剂的糖尿病治疗剂
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
US7314875B2 (en) * 2004-04-13 2008-01-01 Cephalon, Inc. Tricyclic aromatic and bis-phenyl sulfinyl derivatives
US7297817B2 (en) * 2004-04-13 2007-11-20 Cephalon France Thio-substituted arylmethanesulfinyl derivatives
EP1586560A1 (en) * 2004-04-13 2005-10-19 Cephalon, Inc. Thio-substituted arylmethanesulfinyl derivatives
US7449481B2 (en) * 2004-04-13 2008-11-11 Cephalon, Inc. Thio-substituted biaryl-methanesulfinyl derivatives
US7423176B2 (en) * 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
EP1805136A1 (en) * 2004-10-28 2007-07-11 The Institutes for Pharmaceutical Discovery, LLC Substituted phenylalkanoic acids
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP1819673A2 (en) * 2004-11-30 2007-08-22 Plexxikon, Inc. Indole derivatives for use as ppar active compounds
EP1819669A2 (en) * 2004-12-09 2007-08-22 Kalypsys, Inc. Novel inhibitors of histone deacetylase for the treatment of disease
WO2006127133A2 (en) 2005-04-01 2006-11-30 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1896027A4 (en) 2005-06-10 2011-11-30 Donald E Scott TOPICAL COMPOSITIONS AND METHODS FOR TREATING OR INHIBITING SYMPTOMS RELATED TO CARPET TUNNEL SYNDROME, SURFACE FLUX, PSORIASIS, CANDLES, FIBROMYALGIA AND DIABETES
AU2006261841B8 (en) 2005-06-27 2012-12-06 Exelixis Patent Company Llc Pyrazole based LXR modulators
SG165362A1 (en) * 2005-09-07 2010-10-28 Plexxikon Inc Ppar active compounds
EP1931658A2 (en) * 2005-09-07 2008-06-18 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
BRPI0615948A2 (pt) * 2005-09-07 2011-05-31 Plexxikon Inc composto ativo de ppar, sua composição, seu kit e seu uso
WO2007036041A1 (en) * 2005-09-28 2007-04-05 Suleiman Igdoura Sialidase inhibitors for the treatment of cardiovascular disease
UA95613C2 (ru) * 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
EP1962835A2 (en) * 2005-12-21 2008-09-03 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3 receptor antagonist/inverse agonist
US20070155707A1 (en) * 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
KR20080089453A (ko) 2006-01-25 2008-10-06 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
WO2007087506A2 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US7820721B2 (en) * 2006-01-25 2010-10-26 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR20080097418A (ko) * 2006-02-02 2008-11-05 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
US8044243B2 (en) * 2006-02-13 2011-10-25 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2009528375A (ja) * 2006-02-28 2009-08-06 ウェルスタット セラピューティクス コーポレイション 代謝障害を処置するための化合物
CA2647258A1 (en) 2006-03-31 2007-10-18 Wellstat Therapeutics Corporation Combination treatment of metabolic disorders
US20070238183A1 (en) * 2006-04-04 2007-10-11 Stout Robert L Methods for assessment of cardiovascular disease risk
AU2007253929B2 (en) * 2006-05-18 2011-07-21 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
MX2008015640A (es) * 2006-06-09 2009-01-09 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.
MX2009001763A (es) * 2006-08-17 2009-02-25 Wellstat Therapeutics Corp Tratamiento combinado para trastornos metabolicos.
US20080089845A1 (en) * 2006-09-07 2008-04-17 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
WO2008042892A2 (en) * 2006-10-02 2008-04-10 N.V. Organon Fatty acid amide hydrolase inhibitors for energy metabolism disorders
US20080119549A1 (en) * 2006-11-20 2008-05-22 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
WO2008073825A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. Lxr and fxr modulators
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
AU2008240158B2 (en) * 2007-04-11 2014-07-10 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2009091732A1 (en) * 2008-01-15 2009-07-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR101677945B1 (ko) 2008-03-13 2016-11-29 웰스태트 테러퓨틱스 코포레이션 화합물 및 요산을 감소시키기 위한 방법
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
KR101037178B1 (ko) * 2008-04-10 2011-05-26 건국대학교 산학협력단 비뉴클레오시드 계열의 ｃ형 간염 치료 또는 예방제
RU2522458C2 (ru) * 2008-04-30 2014-07-10 Веллстат Терапьютикс Корпорейшн Тетразольные соединения для снижения концентрации мочевой кислоты
WO2009137381A1 (en) * 2008-05-05 2009-11-12 Wellstat Therapeutics Corporation Synthesis of 4-[3-(2,6-dimethylbenzyloxy)phenyl]-4-oxobutanoic acid
US8703991B2 (en) 2008-11-04 2014-04-22 Wellstat Therapeutics Corporation Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids
KR20120039742A (ko) 2009-07-31 2012-04-25 가부시끼가이샤 스텔릭 사이세이 이카가꾸 겐뀨쇼 지방성 간염-간암 모델 동물
JP5806221B2 (ja) * 2009-10-13 2015-11-10 ウェルスタット セラピューティクス コーポレイション 尿酸を減少させる３−置換化合物
WO2012033720A1 (en) 2010-09-08 2012-03-15 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
US20140107166A1 (en) * 2011-02-14 2014-04-17 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors and methods of use thereof
FR2974065B1 (fr) * 2011-04-14 2013-05-10 Snecma Procede de montage d'un moteur d'aeronef sur un pylone et attache moteur pour la mise en oeuvre d'un tel procede.
FR2976943B1 (fr) 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
FR2976942B1 (fr) * 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
FR2999427B1 (fr) 2012-12-17 2015-01-30 Metabolys Composition et kit comprenant des derives de piperazine et de la metformine, leur utilisation dans le traitement du diabete
EP3080070B1 (de) * 2013-12-11 2017-11-01 Bayer CropScience Aktiengesellschaft Verfahren zur herstellung von halogenierten di-substituierten benzylaminen, insbesondere halogenierten dialkylbenzylaminen
EP3411043A4 (en) * 2016-02-01 2019-10-02 Razani, Babak COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROSIS, HEPATATATATOSIS AND OTHER RELATED DISEASES
EP3278802A1 (en) 2016-08-04 2018-02-07 Metabolys New treatment for the non alcoholic steatohepatitis and fibrosis
CN108610285B (zh) * 2017-03-17 2020-04-28 上海柏翱纳吉医药科技有限公司 苯乙酮类化合物、其制备方法及其在防治脂肪肝方面的应用
WO2019224393A1 (en) * 2018-05-25 2019-11-28 University Of Copenhagen Fenofibrate for reducing hypoglycemia in type 1 diabetes/lada
BR112021006907A2 (pt) * 2018-10-11 2021-09-08 Basf As Compostos aromáticos e usos farmacêuticos destes
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5035E (fr) 1902-08-29 1905-12-02 Paul Wilhelm Sieurin Engin à puiser à fond de cale des navires et à élever des matières
GB148830A (en) 1918-12-04 1921-11-10 Aegir Electrische Bordapp Und Device for signalling liquid levels at a distance
FR5035M (ru) * 1964-07-28 1967-05-02
CH560193A5 (ru) 1968-06-14 1975-03-27 Ciba Geigy Ag
JPS4725149U (ru) 1971-04-14 1972-11-21
BE787782A (fr) * 1971-08-20 1973-02-19 Thomae Gmbh Dr K Nouveaux 4-(4-biphenylyl)-butyramides
GB1437781A (en) * 1972-04-04 1976-06-03 Beecham Group Ltd Pyridine derivatives having hypoglycaemic activity
FR2191887A1 (en) 1972-07-07 1974-02-08 Ugine Kuhlmann 7-Substd 5-hydroxy-imidazo pyrimidines - antiinflammatories, and immuno-suppressives, from 2-aminoimidazoline and substd ethyl acetates
DE2252818A1 (de) * 1972-10-27 1974-05-09 Nippon Soda Co Aralkylarylaether oder -thioaether und ihre verwendung als regulatoren fuer das pflanzenwachstum
DE2309986A1 (de) * 1973-02-28 1974-08-29 Menarini Sas N-(o-hydroxybenzoyl)-p-(2-dialkylaminoaethoxy)-phenylamine sowie osubstituierte derivate und quartaere salze derselben
NL7307100A (en) 1973-05-22 1974-11-26 1,3-dimethylpyrogallol derivs pharmaceutical inters - prepd. from (3,5-dimethoxy-benzyloxybenzoyl)acetic acid methyl ester and sulphurylchloride
US4098816A (en) * 1973-08-23 1978-07-04 Beecham Group Limited Polycyclic oxy-aromatic acid
IL45396A0 (en) * 1973-08-23 1974-11-29 Beecham Group Ltd Pharmaceutical compositions containing aryl aralkyl ether and thioether derivatives,certain such novel compounds and their preparation
GB1482195A (en) * 1973-08-23 1977-08-10 Beecham Group Ltd Biologically active phenyl(thio)ether derivatives
US4011321A (en) 1973-12-19 1977-03-08 Smith Kline & French Laboratories Limited Pharmaceutical compositions and methods of inhibiting β-adrenergic receptors
GB1488330A (en) 1973-12-19 1977-10-12 Smith Kline French Lab Dihydropyridazinones
JPS5811874B2 (ja) 1974-03-25 1983-03-04 武田薬品工業株式会社 ピリド （３，４−ｄ） ピリダジンルイノ セイゾウホウ
IE42214B1 (en) 1974-06-18 1980-07-02 Smith Kline French Lab Hydrazinopyredazines
GB1479759A (en) * 1974-11-23 1977-07-13 Lepetit Spa Heterocyclic fused derivatives of indole and quinoline
JPS5225734A (en) * 1975-08-23 1977-02-25 Kyorin Pharmaceut Co Ltd Process for preparation of 4-(4'-halogenobenzyloxy)-bonzoyl acetate
JPS5515460A (en) * 1978-07-20 1980-02-02 Hisamitsu Pharmaceut Co Inc Novel 2-substituted-benzoylpropionic acid derivative
US4268442A (en) * 1978-11-14 1981-05-19 Sagami Chemical Research Center Process for preparing aromatic acetic acid
JPS56115747A (en) 1980-02-19 1981-09-11 Nippon Synthetic Chem Ind Co Ltd:The 2- 2-hydroxyethylamino -3-substituted benzoylpropionic acid, its preparation and germicide
DE3012012A1 (de) 1980-03-28 1981-10-08 Beiersdorf Ag, 2000 Hamburg Substituierte 3-aryl-2-cycloalken-1-one und verfahren zu ihrer herstellung
ZA825227B (en) * 1981-07-22 1984-03-28 Syntex Inc Substituted pyrrolidine cardiovascular system regulators antihypertensives
IT1171604B (it) * 1981-10-22 1987-06-10 Roussel Maestretti Spa Derivati di acido 4-fenil-4-ossobuten-2-oico dotati di proprieta' farmacologiche e loro procedimento di preparazione
DE3370616D1 (en) * 1982-08-06 1987-05-07 Ube Industries Process for producing phenylacetones
US4474809A (en) * 1983-01-20 1984-10-02 American Cyanamid Company Arylglyoxals
JPS6140270A (ja) * 1984-08-01 1986-02-26 Morishita Seiyaku Kk ピリダジノン誘導体
US4874777A (en) 1987-04-10 1989-10-17 Eli Lilly And Company Leukotriene antagonists
JPS63270661A (ja) 1987-04-28 1988-11-08 Taki Chem Co Ltd １−〔２−（４−ヒドロキシベンゾイル）エタノイル〕−２−ピペリドン及びその製造法並びにそれを有効成分とするアルコ−ル発酵促進剤
DE3720317A1 (de) * 1987-06-19 1988-12-29 Sandoz Ag Neue allylaminderivate
JPS6438636A (en) * 1987-08-05 1989-02-08 Ajinomoto Kk Fluorescent analyzer
JPS6463570A (en) 1987-09-03 1989-03-09 Taki Chemical 1-(3-(4-hydroxyphenyl)-3-hydroxypropanoyl)-2-piperidone, its production and plant growth regulator therefrom
JPH041023Y2 (ru) 1987-10-20 1992-01-14
JP2534744B2 (ja) 1988-01-13 1996-09-18 株式会社リコー カラ―画像符号化方式
US4845231A (en) 1988-02-12 1989-07-04 American Home Products Corporation Tetrazoles and their use as hypoglycemic agents
JPH01216961A (ja) * 1988-02-25 1989-08-30 Takeda Chem Ind Ltd １２−リポキシゲネース阻害剤
GB8804457D0 (en) 1988-02-25 1988-03-23 Ciba Geigy Ag Compositions
CA2012681A1 (en) 1989-03-31 1990-09-30 Masayasu Okuhira Quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US4911555A (en) * 1989-05-04 1990-03-27 The Jackson Laboratory Magnetic stirrer for multiple samples
DE3923093A1 (de) 1989-07-13 1991-01-24 Basf Ag Neue 3-methoximinopropionsaeureester und diese enthaltende fungizide
JPH0348603A (ja) * 1989-07-14 1991-03-01 Wakayama Pref Gov 抗菌防臭材料
CA2029219A1 (en) * 1989-11-08 1991-05-09 Mary K. Estes Methods and reagents to detect and characterize norwalk and related viruses
US6572862B1 (en) * 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
JP3310281B2 (ja) * 1989-11-08 2002-08-05 ベイラー カレッジ オブ メディシン ノーワーク及び関連のウィルスを検出し同定するための方法と試薬
US5149737A (en) * 1990-06-18 1992-09-22 Eastman Kodak Company Carboxy containing monomers and polymers and latices prepared from same
DE69113874T2 (de) * 1990-06-21 1996-03-28 Zeneca Ltd Zyklische Ether-Derivate.
AU638840B2 (en) * 1990-07-05 1993-07-08 Sumitomo Chemical Company, Limited Pyrimidine derivative
JPH0495049A (ja) * 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd ビフェニル‐５，５’‐ビス‐アルカン酸誘導体、その製造法およびその用途
JPH04159266A (ja) * 1990-10-19 1992-06-02 Fujisawa Pharmaceut Co Ltd ピリミジノン誘導体
ES2094344T3 (es) 1991-01-02 1997-01-16 Merrell Pharma Inc Compuestos anti-virales.
NL9100770A (nl) * 1991-05-03 1992-12-01 Hubertine Maria Emilie Aalders Opslagdoos voor een bril en contactlenzen.
TW201311B (ru) * 1991-06-17 1993-03-01 Hoffmann La Roche
US5817693A (en) * 1991-11-05 1998-10-06 Cousins; Russell Donovan Endothelin receptor antagonists
ES2164054T3 (es) 1991-11-05 2002-02-16 Smithkline Beecham Corp Antagonistas de receptores de endotelina.
JPH05230009A (ja) * 1992-02-24 1993-09-07 Taisho Pharmaceut Co Ltd アミジン誘導体
JPH08504194A (ja) * 1992-12-01 1996-05-07 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
TW273551B (ru) 1993-05-24 1996-04-01 Wakiei Seiyaku Kk
US5591862A (en) * 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
HUT74179A (en) * 1993-08-19 1996-11-28 Warner Lambert Co Substituted 2(5h)furanone, 2(5h)thiophenone and 2(5h)pyrrolone derivatives, their preparation and their use as endothelin antagonists
IL111613A0 (en) 1993-11-12 1995-01-24 Rhone Poulenc Rorer Ltd Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them
US5665387A (en) * 1994-09-01 1997-09-09 K.U. Leuven Research & Development Methods and compositions for primary and secondary prevention of autoimmune diabetes
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
US7108414B2 (en) * 1995-06-27 2006-09-19 Solid State Opto Limited Light emitting panel assemblies
US5975711A (en) * 1995-06-27 1999-11-02 Lumitex, Inc. Integrated display panel assemblies
US20040135273A1 (en) * 1995-06-27 2004-07-15 Parker Jeffery R. Methods of making a pattern of optical element shapes on a roll for use in making optical elements on or in substrates
US6712481B2 (en) * 1995-06-27 2004-03-30 Solid State Opto Limited Light emitting panel assemblies
US20020058931A1 (en) * 1995-06-27 2002-05-16 Jeffrey R. Parker Light delivery system and applications thereof
US5613751A (en) * 1995-06-27 1997-03-25 Lumitex, Inc. Light emitting panel assemblies
US6185356B1 (en) * 1995-06-27 2001-02-06 Lumitex, Inc. Protective cover for a lighting device
NZ322674A (en) 1995-10-17 1999-08-30 Searle & Co Method of detecting cyclooxygenase-2
GB9521486D0 (en) * 1995-10-20 1995-12-20 Pharmacia Spa Fluoro-substituted benzoylpropionic acid derivatives
GB9522615D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
GB9522617D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butenoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
PL328519A1 (en) 1996-02-19 1999-02-01 Japan Tobacco Inc Antidiabetic therapeutic agent
CN1077107C (zh) 1996-07-19 2002-01-02 武田药品工业株式会社 杂环化合物、其制备和用途
FR2752422B1 (fr) 1996-08-16 1998-11-06 Lipha Composition pharmaceutique contenant des acides 4-oxo-butanoiques
KR100205768B1 (en) * 1996-08-24 1999-07-01 Choongwae Pharm Co Stereo-selective composition of 4-acetoxyazetidinone
US6218427B1 (en) 1996-08-27 2001-04-17 Shionogi & Co., Ltd. Chromene-3-carboxylate derivatives
AU725403B2 (en) * 1996-09-13 2000-10-12 Merck & Co., Inc. Thrombin inhibitors
US6121251A (en) * 1996-10-11 2000-09-19 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
JPH10130241A (ja) 1996-10-31 1998-05-19 Wakunaga Pharmaceut Co Ltd 新規ピリドンカルボン酸誘導体又はその塩及びこれを含有する医薬
CA2263886A1 (en) * 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
IT1289238B1 (it) 1996-12-10 1998-09-29 Bio S S P A Ora Bio S S R L Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina
WO1999011255A1 (en) 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Peroxisome proliferator-activated receptor controllers
US6038332A (en) 1997-09-05 2000-03-14 Digital Biometrics, Inc. Method and apparatus for capturing the image of a palm
CA2304713C (en) 1997-10-14 2003-06-10 Asahi Kasei Kogyo Kabushiki Kaisha Biphenyl-5-alkanoic acid derivatives and use thereof
EP1030665A4 (en) 1997-10-17 2002-11-27 Aventis Pharm Prod Inc THERAPEUTIC USE OF CHINOLINE DERIVATIVES
JP3608929B2 (ja) 1997-12-19 2005-01-12 セントラル硝子株式会社 ポリイミド組成物
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
BR9802163A (pt) 1998-05-29 2000-11-28 Ind E Com De Prod Farmaceutico Composiçoes farmacêuticas para o tratamento de infecções virais compreendendo substâncias neoflavonoides (4-arilcumarinas)
EP1082121A4 (en) 1998-06-03 2003-02-05 Merck & Co Inc HIV integrase
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
AU4543899A (en) * 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6759662B1 (en) * 1998-07-28 2004-07-06 Ce Resources Pte. Ltd. Optical detection system
PT997474E (pt) * 1998-08-14 2004-01-30 Pfizer Agentes antitromboticos
US6255498B1 (en) 1998-10-16 2001-07-03 Millennium Pharmaceuticals, Inc. Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans
US6291503B1 (en) * 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
AU3372800A (en) * 1999-02-23 2000-09-14 Caliper Technologies Corporation Manipulation of microparticles in microfluidic systems
US7364341B2 (en) * 1999-02-23 2008-04-29 Solid State Opto Limited Light redirecting films including non-interlockable optical elements
US6752505B2 (en) * 1999-02-23 2004-06-22 Solid State Opto Limited Light redirecting films and film systems
US20050024849A1 (en) * 1999-02-23 2005-02-03 Parker Jeffery R. Methods of cutting or forming cavities in a substrate for use in making optical films, components or wave guides
US6827456B2 (en) * 1999-02-23 2004-12-07 Solid State Opto Limited Transreflectors, transreflector systems and displays and methods of making transreflectors
JP2002542224A (ja) 1999-04-19 2002-12-10 コーエラカント コーポレイション Ｉｉ型糖尿病の治療薬としてのｐｐａｒ−（ガンマ）作用物質
CA2373146A1 (en) * 1999-05-07 2000-11-16 Quantum Dot Corporation A method of detecting an analyte using semiconductor nanocrystals
DE29923419U1 (de) * 1999-07-01 2001-02-08 Asta Medica Ag, 01277 Dresden Neue Xanthonverbindungen und diese enthaltende Arzneimittel
US6541521B1 (en) * 1999-07-12 2003-04-01 Warner-Lambert Company Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US20030092058A1 (en) * 1999-08-10 2003-05-15 Spaulding Glenn F. Novel flow cytometer
AU778282B2 (en) * 1999-09-17 2004-11-25 Kyorin Pharmaceutical Co. Ltd. O-anisamide derivatives
JP2001181281A (ja) 1999-10-12 2001-07-03 Sato Pharmaceutical Co Ltd 抗菌剤として有用なキノロン誘導体
AU1624801A (en) * 1999-11-19 2001-05-30 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
TW574193B (en) 1999-12-03 2004-02-01 Astrazeneca Ab Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses
US6610351B2 (en) * 2000-04-12 2003-08-26 Quantag Systems, Inc. Raman-active taggants and their recognition
EP1276739A2 (en) 2000-04-24 2003-01-22 Bristol-Myers Squibb Company Heterocycles that are inhibitors of impdh enzyme
US6653332B2 (en) * 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US6555536B2 (en) * 2000-05-12 2003-04-29 Ortho-Mcneil Pharmaceutical, Inc. Biologically active 4H-benzo [1,4]oxazin-3-ones
AU2001271718A1 (en) 2000-06-29 2002-01-14 Smith Kline Beecham Corporation Fatty acid synthase inhibitors
WO2002002101A1 (fr) 2000-07-05 2002-01-10 Ajinomoto Co., Inc. Composes hypoglycemiques
US7354954B1 (en) * 2000-08-10 2008-04-08 Meythaler Jay M Use of GABA agonists for treatment of spastic disorders, convulsions, and epilepsy
ATE542805T1 (de) 2000-08-11 2012-02-15 Nippon Chemiphar Co Ppar-delta aktivatoren
WO2002059077A1 (en) 2001-01-26 2002-08-01 Takeda Chemical Industries, Ltd. Aminoethanol derivatives
CA2449256A1 (en) * 2001-06-07 2002-12-19 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors
EP1461323B1 (en) 2001-06-12 2013-10-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
DE10135027A1 (de) 2001-07-18 2003-02-06 Solvay Pharm Gmbh Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen
JP2003248008A (ja) * 2001-12-18 2003-09-05 Inst Of Physical & Chemical Res 反応液の攪拌方法
JP2006507303A (ja) * 2002-11-01 2006-03-02 ウェルスタット セラピューティクス コーポレイション 代謝障害の処置のための化合物
JP4697962B2 (ja) * 2003-02-13 2011-06-08 ウェルスタット セラピューティクス コーポレイション 代謝性障害の処置のための化合物
CA2521621C (en) * 2003-04-15 2011-11-01 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
ATE450496T1 (de) * 2003-04-22 2009-12-15 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
AU2004237602B2 (en) * 2003-04-30 2009-05-28 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
GB0314078D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
US20060257987A1 (en) 2003-08-20 2006-11-16 Gonzalez Valcarcel Isabel Cris Ppar modulators
US20050262567A1 (en) * 2004-05-19 2005-11-24 Itshak Carmona Systems and methods for computer security
US7319522B2 (en) * 2004-05-27 2008-01-15 Finesse Solutions Llc. Systems and methods for in situ spectroscopic measurements
EP1846751B1 (en) * 2005-01-31 2020-04-22 The Board of Trustees of the University of Illionis Methods and devices for characterizing particles in clear and turbid media
WO2006127133A2 (en) 2005-04-01 2006-11-30 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CA2647258A1 (en) * 2006-03-31 2007-10-18 Wellstat Therapeutics Corporation Combination treatment of metabolic disorders

Also Published As

Publication number Publication date
KR20100031549A (ko) 2010-03-22
BRPI0210383B1 (pt) 2015-08-04
US20130281705A1 (en) 2013-10-24
US6858602B2 (en) 2005-02-22
US7012071B2 (en) 2006-03-14
CN102140064A (zh) 2011-08-03
US20040242692A1 (en) 2004-12-02
US7101910B2 (en) 2006-09-05
KR100965201B1 (ko) 2010-06-24
US20030149107A1 (en) 2003-08-07
NO20130218L (no) 2004-02-11
US20070249719A1 (en) 2007-10-25
WO2002100341A3 (en) 2004-07-01
AU2007203009A1 (en) 2007-07-19
US20080021109A1 (en) 2008-01-24
ES2441874T3 (es) 2014-02-06
CN100344616C (zh) 2007-10-24
US8604083B2 (en) 2013-12-10
NZ530051A (en) 2006-12-22
BR0210383A (pt) 2006-04-04
HUP0600781A2 (en) 2007-01-29
EP1461323A2 (en) 2004-09-29
US6924314B2 (en) 2005-08-02
CA2450221A1 (en) 2002-12-19
US20040077896A1 (en) 2004-04-22
US20040236100A1 (en) 2004-11-25
US6946491B2 (en) 2005-09-20
NO20035526D0 (no) 2003-12-11
US20050004115A1 (en) 2005-01-06
RU2004100306A (ru) 2005-06-10
HK1076805A1 (en) 2006-01-27
US20070249696A1 (en) 2007-10-25
EP1461323A4 (en) 2009-11-11
JP2009221232A (ja) 2009-10-01
RU2341513C2 (ru) 2008-12-20
KR100959356B1 (ko) 2010-05-20
US20050256333A1 (en) 2005-11-17
KR101009472B1 (ko) 2011-01-19
US20040092516A1 (en) 2004-05-13
KR20100110902A (ko) 2010-10-13
AU2007203009B2 (en) 2011-01-20
US20070244172A1 (en) 2007-10-18
JP2013129665A (ja) 2013-07-04
US8487000B2 (en) 2013-07-16
CN102151262A (zh) 2011-08-17
HK1126987A1 (en) 2009-09-18
IL159320A (en) 2013-05-30
AU2002345625B2 (en) 2007-08-02
CN101444496B (zh) 2011-04-13
US8552062B2 (en) 2013-10-08
CA2450221C (en) 2011-12-20
KR20090061080A (ko) 2009-06-15
US20040092518A1 (en) 2004-05-13
US20050090555A1 (en) 2005-04-28
MXPA03011558A (es) 2004-03-26
US20070244171A1 (en) 2007-10-18
AU2011201016A1 (en) 2011-03-31
PL367078A1 (en) 2005-02-21
US20070105958A1 (en) 2007-05-10
JP2005501012A (ja) 2005-01-13
CZ20033394A3 (cs) 2005-03-16
US7329782B2 (en) 2008-02-12
WO2002100341A2 (en) 2002-12-19
US20040097585A1 (en) 2004-05-20
ZA200309627B (en) 2005-08-31
IL219396A0 (en) 2012-06-28
US7045541B2 (en) 2006-05-16
US7041659B2 (en) 2006-05-09
JP5477893B2 (ja) 2014-04-23
JP2009227690A (ja) 2009-10-08
JP4711621B2 (ja) 2011-06-29
EP1461323B1 (en) 2013-10-09
US9133073B2 (en) 2015-09-15
IL219397A (en) 2013-10-31
AU2011201016B2 (en) 2011-11-03
US20070265323A1 (en) 2007-11-15
IL159320A0 (en) 2004-06-01
US7863475B2 (en) 2011-01-04
US20070244141A1 (en) 2007-10-18
US20080015209A1 (en) 2008-01-17
IL219397A0 (en) 2012-06-28
CN101444496A (zh) 2009-06-03
US20040267025A1 (en) 2004-12-30
RU2502723C2 (ru) 2013-12-27
KR101059776B1 (ko) 2011-08-26
IL209842A0 (en) 2011-02-28
US7851494B2 (en) 2010-12-14
KR20050030089A (ko) 2005-03-29
CN1608055A (zh) 2005-04-20
NO333355B1 (no) 2013-05-13
US7547802B2 (en) 2009-06-16
US20080027229A1 (en) 2008-01-31
HU230352B1 (hu) 2016-02-29
US20070265322A1 (en) 2007-11-15
UA82831C2 (ru) 2008-05-26
UA104987C2 (ru) 2014-04-10
US6916848B2 (en) 2005-07-12

Similar Documents

Publication Publication Date Title
RU2008132204A (ru) Соединения для лечения метаболических заболеваний
MEP24608A (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
ATE185558T1 (de) Prostaglandin-synthase hemmer
EP1492173A3 (en) Light emitting device containing a rare earth complex as luminescent medium
DE60235900D1 (de) Osuppressivum
DE602004032431D1 (de) Pyrimidin-verbindungen und diese enthaltende zusammensetzungen zur schädlingsbekämpfung
KR850007975A (ko) 6-클로로벤즈아졸릴옥시아세트아미드의 제조방법
EA200500862A1 (ru) Синоменин и соединения синоменина, синтез и применение
PH12015501098A1 (en) Antituberculous composition comprising oxazole compounds
EA200500122A1 (ru) Новые соединения, фармацевтические композиции, содержащие их, и способы их использования
AR012878A1 (es) Un compuesto derivado de 5'-desoxicitidina, su uso, un proceso para fabricarlo, composiciones farmaceuticas que lo comprende, y un kit que comprende dicha composicion.
SE7601143L (sv) Nytt oxadiazolinonderivat
ES2169242T3 (es) 2-amino-benzoxazinonas para el tratamiento de infecciones virales.
UA88777C2 (en) Amide derivatives
ATE230752T1 (de) Thienodipyridinderivate, ihre herstellung und verwendung
BRPI0416678A (pt) pirazolpirimidinas
DK1156058T3 (da) Fremgangsmåde til fremstilling af (E,Z) 3-(2-aminoethoxyimino)-androstan-6,17-dion og analoger deraf
BG101267A (en) Bacteriacidal composition
MY130817A (en) Herbicides
PT1206448E (pt) Novos analogos de vitamina d
ATE69611T1 (de) Piperazinylalkylpiperazindion-derivate, ihre verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen.
JPS5524183A (en) Substituted nnpyrazolylmethyllhalogenoaceto anilides*their manufacture and herbicidal composition
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие
PT100616A (pt) Agentes hipoglicemicos de tiazolinodiona
DE60222843D1 (de) Hydrophobe Iodverbindung enthaltendes Liposom und dieses enthaltendes Röntgenkontrastmittel

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20140613